210 related articles for article (PubMed ID: 35886877)
1. Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients.
Dragoș ML; Ivanov IC; Mențel M; Văcărean-Trandafir IC; Sireteanu A; Titianu AA; Dăscălescu AS; Stache AB; Jitaru D; Gorgan DL
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886877
[TBL] [Abstract][Full Text] [Related]
2. Differentiation stage of myeloma plasma cells: biological and clinical significance.
Paiva B; Puig N; Cedena MT; de Jong BG; Ruiz Y; Rapado I; Martinez-Lopez J; Cordon L; Alignani D; Delgado JA; van Zelm MC; Van Dongen JJ; Pascual M; Agirre X; Prosper F; Martín-Subero JI; Vidriales MB; Gutierrez NC; Hernandez MT; Oriol A; Echeveste MA; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Morgan GJ; Orfao A; Blade J; Mateos MV; Lahuerta JJ; San-Miguel JF
Leukemia; 2017 Feb; 31(2):382-392. PubMed ID: 27479184
[TBL] [Abstract][Full Text] [Related]
3. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
[TBL] [Abstract][Full Text] [Related]
4. High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma.
Kosztolányi S; Kiss R; Atanesyan L; Gángó A; de Groot K; Steenkamer M; Jáksó P; Matolcsy A; Kajtár B; Pajor L; Szuhai K; Savola S; Bödör C; Alpár D
J Mol Diagn; 2018 Nov; 20(6):777-788. PubMed ID: 30096382
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic characterization of normal and abnormal plasma cells in bone marrow of newly diagnosed multiple myeloma patients.
Awasthi NP; Mishra S; Gupta G; Kumari S; Bajpayee A; Singh P; Husain N
Indian J Pathol Microbiol; 2023; 66(2):295-300. PubMed ID: 37077071
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
Paiva B; Gutiérrez NC; Chen X; Vídriales MB; Montalbán MÁ; Rosiñol L; Oriol A; Martínez-López J; Mateos MV; López-Corral L; Díaz-Rodríguez E; Pérez JJ; Fernández-Redondo E; de Arriba F; Palomera L; Bengoechea E; Terol MJ; de Paz R; Martin A; Hernández J; Orfao A; Lahuerta JJ; Bladé J; Pandiella A; Miguel JF;
Leukemia; 2012 Aug; 26(8):1862-9. PubMed ID: 22333880
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
Mateo G; Montalbán MA; Vidriales MB; Lahuerta JJ; Mateos MV; Gutiérrez N; Rosiñol L; Montejano L; Bladé J; Martínez R; de la Rubia J; Diaz-Mediavilla J; Sureda A; Ribera JM; Ojanguren JM; de Arriba F; Palomera L; Terol MJ; Orfao A; San Miguel JF; ;
J Clin Oncol; 2008 Jun; 26(16):2737-44. PubMed ID: 18443352
[TBL] [Abstract][Full Text] [Related]
10. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
[TBL] [Abstract][Full Text] [Related]
11. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features.
Schmidt-Hieber M; Pérez-Andrés M; Paiva B; Flores-Montero J; Perez JJ; Gutierrez NC; Vidriales MB; Matarraz S; San Miguel JF; Orfao A
Haematologica; 2011 Feb; 96(2):328-32. PubMed ID: 20971816
[TBL] [Abstract][Full Text] [Related]
12. Quantification of circulating clonal plasma cells by multiparametric flow cytometry as a prognostic marker in patients with newly diagnosed multiple myeloma.
Sathya P; Kayal S; Srinivas BH; Hamide A; Kar R
Int J Lab Hematol; 2023 Dec; 45(6):917-926. PubMed ID: 37632156
[TBL] [Abstract][Full Text] [Related]
13. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.
Alpar D; de Jong D; Holczer-Nagy Z; Kajtar B; Savola S; Jakso P; David M; Kosztolanyi S; Kereskai L; Pajor L; Szuhai K
Genes Chromosomes Cancer; 2013 Sep; 52(9):785-93. PubMed ID: 23720363
[TBL] [Abstract][Full Text] [Related]
14. CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival.
Gross Even-Zohar N; Pick M; Hofstetter L; Shaulov A; Nachmias B; Lebel E; Gatt ME
J Clin Med; 2022 May; 11(10):. PubMed ID: 35629039
[TBL] [Abstract][Full Text] [Related]
15. Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma.
Tian M; Liu Z; Han M; Liu H; Xiang C; Mi F; Deng L; Meng N; Fu R
Cytometry B Clin Cytom; 2022 Jan; 102(1):44-49. PubMed ID: 34057806
[TBL] [Abstract][Full Text] [Related]
16. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
17. Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine?
Rengifo LY; Smits S; Buedts L; Delforge M; Dehaspe L; Tousseyn T; Boeckx N; Lehnert S; Michaux L; Vermeesch JR; Vandenberghe P; Dewaele B
Cancer Treat Res Commun; 2021; 28():100380. PubMed ID: 33962213
[TBL] [Abstract][Full Text] [Related]
18. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
19. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
[TBL] [Abstract][Full Text] [Related]
20. [Immunophenotype characteristics of patients with multiple myeloma in different risk stratification].
Hu K; Wang J; Zhu MX; Wang YF; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1624-7. PubMed ID: 25543486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
